References
- Cersosimo RJ. Gefitinib: an adverse effects profile. Expert Opin Drug Saf 2006;5:469-479. https://doi.org/10.1517/14740338.5.3.469
- Yan X, Li M, Jiang M, Zou LQ, Luo F, Jiang Y. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective analysis of 1711 lung cancer cases. Cancer 2009;115:5018-5025. https://doi.org/10.1002/cncr.24559
- Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev 2011;20:156-174. https://doi.org/10.1183/09059180.00001011
- Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006;43:577-584. https://doi.org/10.1086/505870
-
Brooks MB. Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-
$\alpha$ mediated inflammatory diseases. Oncologist 2013;18:e3-e5. https://doi.org/10.1634/theoncologist.2012-0219
Cited by
- Dexamethasone/gefitinib : Invasive pulmonary aspergillosis: case report vol.1690, pp.1, 2018, https://doi.org/10.1007/s40278-018-42148-4
- CT Halo sign: A systematic review vol.124, pp.None, 2018, https://doi.org/10.1016/j.ejrad.2020.108843